3-甲氧基-4-甲基苯甲醛 | 24973-22-6

• 物质功能分类: 化学试剂 - 有机试剂 - 芳香醛(含缩醛,半缩醛)
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-甲氧基-4-甲基苯甲醛
• 中文别名: 4-甲基-3-甲氧基苯甲醛
• 英文名称: 3-methoxy-4-methylbenzaldehyde
• CAS: 24973-22-6
• 化学式: C₉H₁₀O₂
• mdl: MFCD04114050
• 分子量: 150.177
• InChiKey: TVDHPUFLDYYBPO-UHFFFAOYSA-N

物化性质

• 熔点：
  40.5-41.5
• 沸点：
  246.2±20.0 °C(Predicted)
• 密度：
  1.062±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2912299000
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  3-甲氧基-4-甲基苯甲醛 在 W-2 Raney Ni 乙酸铵 、 sodium dihydrogenphosphate 、 acetate buffer 作用下， 以 乙醇 为溶剂， 反应 4.0h， 生成 1-(3-methoxy-4-methylphenyl)-2-propanone
  参考文献：
  名称：

  Synthesis and pharmacological examination of 1-(3-methoxy-4-methylphenyl)-2-aminopropane and 5-methoxy-6-methyl-2-aminoindan: similarities to 3,4-(methylenedioxy)methamphetamine (MDMA)

  摘要：

  The racemate and the enantiomers of 1-(3-methoxy-4-methylphenyl)-2-aminopropane (6) and racemic 5-methoxy-6-methyl-2-aminoindan (11) were tested for stimulus generalization in the two-lever drug-discrimination paradigm. Both 6 and 11 were found to substitute with high potency in 3,4-(methylenedioxy)methamphetamine (1) and (S)-1-(1,3-benzodioxol-5-yl)-2-(methylamino)butane (2) trained rats. In the latter assay, both enantiomers of 6 had identical potencies, but their dose-response curves were not parallel. Racemic 6, but not 11, partially substituted for LSD. Racemic 6 and 11 did not substitute in (S)-amphetamine-trained rats. All of the test compounds were potent inhibitors of [H-3]-5-HT uptake into synaptosomes in vitro, with the S enantiomer of 6 being most active. Rat brain monoamine levels were unaltered 1 week following a single high dose (10 or 20 mg/kg, sc) of 6 or 11, or two weeks following a subacute dosing regimen (20 mg/kg, sc, twice a day for 4 days). In addition, radioligand-binding parameters in rat brain homogenate with the 5-HT uptake inhibitor [H-3]proxetine were unchanged after subacute dosing with either racemic 6 or 11. The results indicate that compounds 6 and 11 have animal behavioral pharmacology similar to the methylenedioxy compounds 1 and 2, but that they do not induce the serotonin neurotoxicity that has been observed for the latter two drugs.

  DOI：

  10.1021/jm00109a020
• 作为产物：
  描述：

  4-甲基-3-硝基苯甲醛 在 氢氧化钾 作用下， 生成 3-甲氧基-4-甲基苯甲醛
  参考文献：
  名称：

  丝裂霉素的合成研究； 2。分子内Wittig烯化合成有丝分裂骨架

  摘要：

  描述了使用分子内维蒂希烯化反应作为环化反应的苯并吡咯烷衍生物的有效制备方法。随后的维尔斯迈尔反应导致有丝分裂框架。

  DOI：

  10.1002/jlac.198519850712

文献信息

• New Drug Delivery System for Crossing the Blood Brain Barrier
  申请人：Lipshutz H. Bruce

  公开号：US20070203080A1

  公开（公告）日：2007-08-30

  New ubiquinol analogs are disclosed, as well as methods of using these compounds to deliver drug moieties to the body.

  新的泛醌类似物被披露，以及利用这些化合物将药物基团输送到人体的方法。
• 3-Aminocyclopentanecarboxamides as Modulators of Chemokine Receptors
  申请人：Xue Chu-Biao

  公开号：US20070149532A1

  公开（公告）日：2007-06-28

  The present invention is directed to compounds of Formula I: I which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or activity.

  本发明涉及化合物I的化合物：I，这些化合物是趋化因子受体的调节剂。本发明的化合物及其组合物在治疗与趋化因子受体表达和/或活性相关的疾病方面是有用的。
• <i>trans</i>-Directing Ability of the Amide Group: Enabling the Enantiocontrol in the Synthesis of 1,1-Dicarboxy Cyclopropanes. Reaction Development, Scope, and Synthetic Applications
  作者：David Marcoux、Sébastien R. Goudreau、André B. Charette

  DOI：10.1021/jo902066y

  日期：2009.12.4

  enantioselective formation of 1,1-cyclopropane diesters via the metal-catalyzed cyclopropanation of olefins. The strategies envisioned to achieve such a goal are discussed as well as the results that led us to the discovery of the powerful trans-directing ability of the amide group in Rh(II)-catalyzed cyclopropanation reactions. We show how this feature enables a solution for the stereoselective synthesis

  在本文中，我们描述了通过金属催化的烯烃环丙烷化对1,1-环丙烷二酯对映选择性形成的努力。讨论了为实现这一目标而设想的策略，以及导致我们发现功能强大的跨平台交易的结果。Rh（II）催化的环丙烷化反应中酰胺基的定向能力。我们展示了此功能如何实现1,1-二羧基环丙烷衍生物的立体选择性合成的解决方案。讨论了范围和局限性，并论证了这些新形成的环丙烷显示出与1,1-环丙烷二酯相似的反应性。相反，可以从市售烯烃中分两步获得1，1-环丙烷二酯。该方法的潜在效用通过数个官能团转化及其在（S）-（+）-姜黄素，（S）-（+）-核苷，（S）-（+）-核苷醇，（+）-七茂烯，（±）-黄根醇和（±）-2-羟基cal烯。
• [EN] 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS<br/>[FR] DERIVES DE PIPERIDINE 1,4 DISUBSTITUEE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE 11-BETAHSD1
  申请人：ASTRAZENECA AB

  公开号：WO2004033427A1

  公开（公告）日：2004-04-22

  The use of a compound of formula (I) in the manufacture of a medicament for use in the inhibition of 11βHSD1 is described.

  使用式(I)的化合物制造用于抑制11βHSD1的药物。
• 1,2,4,5-Tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them
  申请人：Peglion Jean-Louis

  公开号：US20090069296A1

  公开（公告）日：2009-03-12

  Compounds of formula (I): wherein: R 1 represents a hydrogen atom or a group selected from cycloalkyl, benzyl and optionally substituted alkyl, R 2 , R 3 , R 4 and R 5 each represent a hydrogen atom or a hydroxy, methyl, —OSO 2 R 10 , —OCOR 10 or optionally substituted alkoxy group, or R 2 and R 3 , or R 3 and R 4 , or R 4 and R 5 together form a group —O—(CH 2 ) q —O—, —O—CH═CH—O— or —O—CH═CH—, R 6 , R 7 , R 8 and R 9 each represent a hydrogen atom or an alkoxy group, or R 6 and R 7 , or R 7 and R 8 , or R 8 and R 9 together form a group —O—(CH 2 ) q —O—-, R 10 represents a group selected from linear or branched C 1 -C 6 alkoxy, NR 11 R′ 11 and optionally substituted alkyl, R 11 and R′ 11 each represent a hydrogen atom or an alkyl group, or R 11 and R′ 1 together with the nitrogen atom carrying them form an optionally substituted, monocyclic or bicyclic, nitrogen-containing heterocycle, X represents O, NH or CH 2 , m and p each represent 0 or 1, n and q each represent 1 or 2, in racemic form or in the form of optical isomers,and also addition salts thereof with a pharmaceutically acceptable acid. Medicinal products containing the same which are useful in treating various pathologies.

  式（I）的化合物： 其中： R1代表氢原子或从环烷基、苄基和可选择地取代的烷基中选择的基团， R2、R3、R4和R5分别代表氢原子或羟基、甲基、—OSO2R10、—OCOR10或可选择地取代的烷氧基，或R2和R3，或R3和R4，或R4和R5一起形成一个基团—O—（CH2）q—O—，—O—CH═CH—O—或—O—CH═CH—， R6、R7、R8和R9分别代表氢原子或烷氧基，或R6和R7，或R7和R8，或R8和R9一起形成一个基团—O—（CH2）q—O—-， R10代表从线性或支链C1-C6烷氧基、NR11R′11和可选择地取代的烷基中选择的基团， R11和R′11分别代表氢原子或烷基基团，或R11和R′1与携带它们的氮原子一起形成一个可选择地取代的、单环或双环、含氮杂环， X代表O、NH或CH2， m和p各自代表0或1， n和q各自代表1或2， 以外消旋形式或光学异构体形式，以及其与药学上可接受的酸的加合盐。 含有这些化合物的药物，对治疗各种病理有用。